1Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Catacer,2001.37(Suppl 4) :16-22.
2Leonard B, Saltz. Neal J. et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology.2004.22(7) : 1201-1208.
3Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation.apoptosis.and radiosensitivity in squamous cell carcinorma of the head and neck. Cancer Res. 1999.59:1935-1940.
4Guslafson NF.Saltz L,Cunningham D.et al. Safety profile of cetuximab in patients with metastatic colorectal cancer. Gastrointestinal Cancers Sympos um 2004 Abstract:237.
5National PBM Drug Monograph Cetuximab (Erbilux^TM). VA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel.2004.1-10.
6Vega-Villegas E, Awada R,Mesia L,et al. A phase Ⅰ study of cetuximab in combination with eisplatin or carhoplatin and 5-FU in patients with recurrent or metastatic squamous cell carcinoma of lhe head and neck. Proceedings of the American Association for Cancer Research,2004, Abstract : 2020.
7Harding J. Burtness B. Cetuximab.. An epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc).2005.41(2):107-127.
8David E. Cetuximab in metastatic colorectal cancer. London Cancer New Drugs Group-APC/DTC Briefing 2005.7( 1 ): 1-10.
9David C.Yves H.Salvatore S.et al. Cetuximab monotherapy and celuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.New Engl J Med,2004,351(4):337-345.
